What is EnsiliTech?
EnsiliTech is a pioneering biotech firm that has developed a groundbreaking Ensilication® technology. This patented innovation addresses a critical challenge in the biopharmaceutical supply chain by eliminating the need for cold-chain logistics. The technology protects sensitive materials such as vaccines, antibodies, and enzymes within a temperature-stable silica matrix, offering a robust and reliable alternative to traditional refrigerated transport and storage. This advancement positions EnsiliTech as a key player in enhancing the accessibility and stability of vital biological products globally.
How much funding has EnsiliTech raised?
EnsiliTech has raised a total of $7.5M across 2 funding rounds:
Other Financing Round
$1.4M
Seed
$6M
Other Financing Round (2023): $1.5M with participation from QantX, Fink Family Law Offices, UK Research & Innovation, Elbow Beach Capital, and Science Angel Syndicate
Seed (2025): $6M led by QantX, Eos Advisory, Fink Family Law Offices, and Calculus Capital
Key Investors in EnsiliTech
QantX
QantX is a venture capital firm focused on investing in high-impact innovations within technology and science-based sectors, particularly in the South West UK. They support early-stage founders with capital and expertise, aiming to drive innovation and economic growth.
Eos Advisory
Eos Advisory is an investment firm that bridges innovation with global opportunities, focusing on science and technology with an emphasis on quality of life and environmental sustainability. They partner with various investors to create financial returns and positive impact.
Fink Family Law Offices
Fink Family Law, LLC provides specialized legal representation in family law matters, prioritizing client interests and community needs. While their primary focus is legal services, their participation in this funding round indicates a broader interest in supporting innovative ventures.
What's next for EnsiliTech?
With the recent infusion of major enterprise-level funding, EnsiliTech is poised for significant expansion and further development of its Ensilication® technology. The strategic investment signals strong confidence from backers in the company's potential to disrupt the biopharmaceutical logistics sector. Future efforts will likely focus on scaling production, expanding market reach, and forging new partnerships to integrate this innovative storage solution across a wider range of applications, potentially including global health initiatives and advanced research programs. The company's trajectory suggests a move towards broader commercialization and establishing its technology as an industry standard.
See full EnsiliTech company page
